CHARM Therapeutics 🤖 AI Native

Healthcare 📍 London, United Kingdom 👥 11-50 employees 💰 $162.7M raised 📅 Founded 2021

CHARM's lead program is a next-generation menin inhibitor for the treatment of acute myeloid leukemia (AML). Unlike first-generation menin inhibitors that rapidly lose potency due to menin resistance mutations, CHARM's candidates are specifically designed to maintain potency against all known clinical resistance mutati

🌐 Website in LinkedIn ← All Companies

📊 Company Overview

Sector

Healthcare

Country

United Kingdom

Employees

11-50

Total Raised · Series B

$162.7M

Founded

2021

Cloud

GCP

Email

Mimecast

☁️ Cloud Infrastructure

GCP Detected Cloud Provider

Detected via HTTP headers

Workspace	Mimecast
CDN	🔒 Subscribers only

Detected via DNS records and HTTP response headers as of 2026-06-13.

💰 Estimated Cloud Spend

$108K – $270K / year on GCP

🛠 Tech Stack & Marketing

Ad Platforms	🔒 Subscribers only
Analytics & CRM	Google Analytics
CMS / Platform	WordPress
Frontend Stack	🔒 Subscribers only

Detected from CHARM Therapeutics's public homepage as of 2026-06-13.

🔍 Compare with Similar Companies

Same sector (Healthcare), similar size

1-10 ☁️ Unknown

Central Printing Group

1-10 ☁️ Unknown

Ortho Clinical Diagnostics Holdings Plc

1-10 ☁️ Azure

Data detected 2026-06-13 · Methodology · Suggest a correction